ESALF News and Press, Eisai Co Ltd From 05/13/22

Eisai Co., Ltd. (ESALF) Q4 2022 Earnings Conference Call May 13, 2022 3:30 AM ET Company Participants Haruo Naito - CEO Ivan Cheung - Senior VP & President of Neurology Business Group Teruyuki Masaka - VP & Chief Planning Officer Takashi Owa - Senior VP, President & Chief Discover...

The adj. earnings per share of Biogen (NASDAQ:BIIB) fell short of Street forecasts by as much as $0.74 in1Q 2022 as the as the company said it recognized $0.76 charge to reflect write offs related to the Alzheimer’s drug Aduhelm which was approved by the FDA last year. While the FDA si...

At this point, Eli Lilly's donanemab performs only a tick better than Biogen's aducanumab/Aduhelm for Alzheimer's disease. The FDA may grant accelerated approval to donanemab as it did for aducanumab based on the removal of amyloid plaques as a surrogate biomarker. Medicare, thoug...

Efforts to manipulate growth factors including those being undertaken by Athira and Synaptogenix are unlikely to be successful because the pathway through which growth factors work is inhibited by nitration. Anti-amyloid treatments such as those being undertaken by Biogen and Eisai, E...

Biogen (NASDAQ:BIIB) said it submitted the final study protocol to the U.S. Food and Drug Administration for a confirmatory phase 4 ENVISION trial of its Alzheimer’s disease (AD) drug Aduhelm, developed with Eisai (OTCPK:ESALF) (OTCPK:ESALY). The company said the co...

Following a sharp decline, the clinical-stage pharma company, Amylyx (NASDAQ:AMLX -41.3%) pared losses after Evercore ISI issued favorable views on the briefing documents released by the U.S. regulators on the company’s candidate for amyotrophic lateral sclerosis, AMX0035. Ahead of an ...

The Japanese Ministry of Health, Labour and Welfare (MHLW) approved Gilead Sciences (NASDAQ:GILD), Galapagos (NASDAQ:GLPG) and Eisai's (OTCPK:ESALF) drug Jyseleca (filgotinib) to treat patients with moderate-to-severe active ulcerative colitis (UC), an inflammatory bowel diseas...

UBS is maintaining its buy rating on Biogen (BIIB +2.2%) despite Tuesday's announcement the biotech is taking sole commercial rights to Alzheimer's treatment Aduhelm (aducanumab) from partner Eisai (OTCPK:ESALY -0.1%). The firm has a $269 price target (~36% upside based on Tuesday's close). A...

The following slide deck was published by Eisai Co., Ltd. in conjunction with their 2021 Q3 earnings call. For further details see: Eisai Co., Ltd. 2021 Q3 - Results - Earnings Call Presentation

Eisai Co., Ltd. (ESALF) Q3 2022 Earnings Conference Call February 3, 2022, 2:00 AM ET Company Participants Dr. Ryohei Yanagi - Chief Financial Officer Ivan Cheung - President, Neurology Business Group Dr. Takashi Owa - President, Oncology Business Group Teruyuki Masaka - In-charge, Business P...